Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  Agentix Corp.    AGTX

AGENTIX CORP.

(AGTX)
  Report
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

AGENTIX CORP. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securities, Changes in Control or Registrant, Financial Statements and Exhibits (form 8-K)

05/29/2020 | 05:28pm EST

Item 1.01 Entry into a Material Definitive Agreement.

On May 28, 2020, Agentix Corp., a Nevada corporation (the "Company"), entered into a Share Exchange Agreement (the "Share Exchange Agreement"), by and among the Company, and GSL Healthcare, Inc., a Nevada corporation ("GSL Healthcare"), and the holders of common stock of GSL Healthcare, which consisted of two stockholders.

Under the terms and conditions of the Share Exchange Agreement, the Company offered and sold 27,932,271 shares of common stock of the Company in consideration for all of the issued and outstanding shares of common stock of GSL Healthcare. The effect of the issuance is that former two GSL Healthcare shareholders now hold approximately 88.0% of the issued shares of common stock of the Company, and HSL Healthcare is now a wholly-owned subsidiary of the Company. GSL Healthcare has a general plan to be a health and wellness business. Until such time as the Company can formulate GSL Healthcare's general business plan, the Company is not changing its current business.

Item 2.01 Completion of Acquisition or Disposition of Assets

The information disclosed in Item 1.01 (Entry of Material Definitive Agreement) of this Form 8-K is hereby incorporated by reference into this Item 2.01.

Item 3.02 Unregistered Sales of Equity Securities.

The information disclosed in Item 1.01 (Entry of Material Definitive Agreement) of this Form 8-K is hereby incorporated by reference into this Item 2.01. We made the offer and sale of the 27,932,271 shares of common stock of the Company pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, in a non-public offering to two sophisticated persons who had access to registration-type of information about the Company.

Item 5.01 Changes in Control of Registrant.

Information disclosed in Item 1.01 (Entry of Material Definitive Agreement) of this Current Report on Form 8-K is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits




(d) Exhibits:



Exhibit   Description

  2.1       Share Exchange Agreement, dated May 28, 2020, by and among the Agentix
          Corp., GSL Healthcare, Inc., a Nevada corporation, and the holders of
          common stock of GSL Healthcare, Inc.





2

© Edgar Online, source Glimpses

All news about AGENTIX CORP.
01/13AGENTIX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
2020AGENTIX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
2020Agentix Biopharma CEO, Rudy Mazzocchi, Discusses the Company's Growth Strateg..
NE
2020AGENTIX : Completion of Acquisition or Disposition of Assets, Financial Statemen..
AQ
2020AGENTIX CORP. : Other Events (form 8-K)
AQ
2020AGENTIX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
2020AGENTIX CORP. : Change in Directors or Principal Officers (form 8-K)
AQ
2020AGENTIX CORP. : Entry into a Material Definitive Agreement, Completion of Acquis..
AQ
2020AGENTIX CORP. : Change in Directors or Principal Officers (form 8-K)
AQ
2020AGENTIX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -0,87 M - -
Net cash 2020 0,24 M - -
P/E ratio 2020 -79,4x
Yield 2020 -
Capitalization 43,1 M 43,1 M -
EV / Sales 2019
EV / Sales 2020 -
Nbr of Employees -
Free-Float 8,55%
Chart AGENTIX CORP.
Duration : Period :
Agentix Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
NameTitle
Rudy A. Mazzocchi Chairman, President, CEO, CFO & CAO
Martin Schroeder Chief Scientific Officer
Scott Stevens Director
Rehan Huda Director
Salman Hoda Senior VP-Portfolio & Business Development
Sector and Competitors
1st jan.Capitalization (M$)
AGENTIX CORP.100.00%34
CSL LIMITED-4.25%93 519
SAMSUNG BIOLOGICS CO.,LTD.-3.63%47 194
BIOGEN INC.12.65%42 447
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.-10.55%34 810
ALEXION PHARMACEUTICALS, INC.0.29%34 293